1 active not recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow merestinib: new trials by email Literature Review of merestinib trials Research Report on merestinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Merestinib - Carcinoma, Non-Small-Cell Lung, Solid Tumor | Phase 2 | Terminated | Dana-Farber Cancer Institute | 12 | 2016-11-11 | 2024-04-11 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Ramucirumab, Merestinib, Cisplatin - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 309 | 2016-05-19 | 2026-07-22 |
Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1)
United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Mexico (1) · Russia (1) · South Korea (1) · Spain (1) · Sweden (1)
Mark Awad, MD (1)
2015 (1)